Prestige Consumer Healthcare Inc. (NYSE:PBH) reported financial results for its fiscal third quarter ended December 31, 2025, delivering a mixed performance against analyst expectations. The company's revenue slightly exceeded its own outlook but fell short of Wall Street forecasts, while adjusted earnings per share also missed consensus estimates. The market's initial reaction was negative, with the stock trading down over 5% in pre-market activity.
Earnings vs. Estimates: A Narrow Miss
The consumer healthcare company posted third-quarter revenue of $283.4 million. While this figure surpassed the company's internal outlook, it came in just below the analyst consensus estimate of approximately $284.8 million. The more significant miss was on the bottom line. Prestige reported non-GAAP adjusted diluted earnings per share (EPS) of $1.14 for the quarter, which was lower than the $1.22 reported in the prior-year period and below the analyst estimate of $1.16.
Key Q3 FY2026 Results vs. Estimates:
- Reported Revenue: $283.4 million
- Analyst Revenue Estimate: ~$284.8 million
- Verdict: Slight miss
- Adjusted Diluted EPS: $1.14
- Analyst EPS Estimate: $1.16
- Verdict: Miss
Market Reaction and Updated Guidance
The pre-market decline of more than 5% suggests investors were disappointed by the earnings miss and the company's revised full-year outlook. Management narrowed its fiscal 2026 guidance, now expecting revenue of approximately $1.10 billion and adjusted diluted EPS of approximately $4.54. This revenue forecast sits below the current analyst consensus estimate of $1.119 billion for the full year, potentially contributing to the negative sentiment.
Updated Fiscal 2026 Outlook vs. Analyst Expectations:
- Company Revenue Outlook: ~$1.10 billion
- Analyst Revenue Estimate: $1.119 billion
- Company Adjusted EPS Outlook: ~$4.54
- Analyst EPS Estimate (implied): ~$4.60 (based on provided data)
Press Release Highlights and Challenges
The earnings report highlighted several key operational and financial points. CEO Ron Lombardi noted the company "exceeded our third quarter revenue outlook and delivered solid profitability," attributing the results to a diverse business model and strong financial profile. However, the company continues to navigate significant headwinds.
Primary Factors Impacting Performance:
- Supply Chain Constraints: The company cited a "limited ability to supply demand" for its Clear Eyes® eye care products as the primary driver behind a year-over-year revenue decline of 2.4%. This issue affected both its North American and International OTC Healthcare segments.
- Strategic Acquisition: The quarter saw the successful closure of the acquisition of Pillar5 Pharma, Inc., an eye care supplier, which is expected to help address the Clear Eyes® supply issues in the long term.
- Strong Cash Generation & Shareholder Returns: A standout positive was the robust generation of free cash flow, which reached $208.8 million for the first nine months of the fiscal year. This financial strength allowed the company to repurchase approximately 0.8 million shares in Q3, totaling $45.8 million, as part of its ongoing capital return program.
Looking Ahead
The company's narrowed guidance reflects a "continued challenging consumer environment." Management's focus remains on rebuilding supply chain capacity for Clear Eyes®, with expectations for improvement in coming quarters. The maintained outlook for free cash flow of $245 million or higher underscores the stability of the company's financial model despite near-term operational challenges.
For a detailed breakdown of past earnings and future analyst estimates for Prestige Consumer Healthcare, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.